Ordering Recommendation

Monitor for development of EGFR T790M drug-resistant mutation in patients administered tyrosine kinase inhibitor (TKI) therapy for EGFR-mutant non-small cell lung cancer. Monitor response to therapy and disease progression in patients treated with EGFR T790M-specific TKIs.

Mnemonic
EGFR T790M
Methodology

Polymerase Chain Reaction

Performed

Varies

Reported

7-12 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Whole blood in two 10 mL Cell-Free DNA (cfDNA) BCT Tubes (ARUP Supply #52358) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. Also acceptable: CSF collected in a sterile container.

Specimen Preparation

Whole Blood: Transport 20 mL whole blood. (Min: 16 mL)
CSF: Transport 4 mL CSF. (Min: 4 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

FFPE tissue. Whole Blood collected in non-cfDNA BCT tubes.

Remarks
Stability

Whole Blood: Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable
CSF: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: Unacceptable

Reference Interval
Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note
Hotline History
N/A
CPT Codes

81235

Components
Component Test Code* Component Chart Name LOINC
2012869 EGFR T790M Result 55769-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
EGFR T790M Mutation Detection in Circulating Tumor DNA by Digital Droplet PCR